Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Age ≥ 75 or age 65-74 with at least 1 of the following comorbidities: arterial hypertension, diabetes, obesity, chronic obstructive pulmonary disease, heart disease, chronic kidney disease~* Last 48 hours: (A)Axillary temperature ≥ 37.5oC or febrile equivalent, combined with (a) dry cough and/or (b) breathing difficulty and/or (c) odinophagia and/or (d) anosmia/dysgeusia and/or (e) any of the following symptoms: fatigue, anorexia, myalgias or rhinorrhea.~* Confirmed diagnosis SARS-Cov2 by RT-PCR~* Give Informed consent~Exclusion Criteria:~* Severe respiratory disease~* Cardiac insufficiency,~* Chronic renal failure,~* Primary hypogammaglobulinemias,~* Myelodysplastic syndromes,~* Chronic linfoproliferative syndromes,~* Monoclonal gammapathies,~* Known hypersensitibility,~* Active cancer,~* HIV, HBV or HCV infection,~* Chronic administration of immunosuppressants,~* Body transplant history,~* Chronic liver disease, Chronic lung disease with oxygen requirement.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasma (Type: EXPERIMENTAL): Convalescent plasma with an IgG titer against SARS-CoV2
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).